A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema – ORBIT-EXPANSE (NCT07204938)

STAR-0215-302

This trial is Coming soon
Registration number NCT07204938
This is an extension study for patients with Hereditary Angioedema who participated in the STAR-0215-301 study.

Program & service

This trial is being run with the Heart & Lung service, and as part of the Respiratory program.

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

A/Prof Celia Zubrinich

Key inclusion data

NOT RECRUITING: Patients must have completed STAR-0215-301 to be eligible to participate in extension study STAR-0215-302.

More information

To find out more about this clinical trial, please review full details on the ANZCTR website.

View on ANZCTR

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.